Please check your internet connection and try again.
# Dihydrocodeinone 20mg
## Overview
Dihydrocodeinone (also known as dihydrocodeine) is a semi-synthetic opioid agonist with antitussive and analgesic properties. It is a Schedule III controlled substance.
## Primary Indications
* Symptomatic relief of moderate to moderately severe pain.
* Suppression of cough.
## Adult Dosing
* **Pain:** Typically 10-20 mg orally every 4-6 hours as needed. Doses may be titrated up to 20 mg every 4 hours for severe pain, not to exceed 120 mg in 24 hours.
* **Cough:** Typically 10 mg orally every 4-6 hours as needed. Maximum dose is usually not specified, but it is important to consider the total opioid exposure.
*Note: Specific dosing may depend on local protocols and patient-specific factors.*
## Pediatric Dosing
The use of dihydrocodeinone in pediatric patients is generally not recommended due to safety concerns, including an increased risk of respiratory depression and death. If used, dosing should be individualized and carefully monitored by a healthcare professional. Specific pediatric dosing is not well-established and should only be guided by expert clinical judgment and available literature, considering the patient's weight and clinical status.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dosage reduction may be necessary.
* **Renal Impairment:** Use with caution. Dosage reduction may be necessary, especially in severe impairment.
* **Elderly:** Increased sensitivity to opioids; use with caution and consider lower initial doses.
## Contraindications
* Hypersensitivity to dihydrocodeinone or any component of the formulation.
* Significant respiratory depression.
* Acute or severe asthma or other obstructive airway disease.
* Known or suspected paralytic ileus.
* Use in children under 6 years of age for cough due to risk of serious adverse events, including death.
## Adverse Effects
* **Common:** Sedation, dizziness, lightheadedness, constipation, nausea, vomiting, pruritus.
* **Serious:** Respiratory depression, apnea, circulatory depression, hypotension, hypertension, opioid dependence, withdrawal symptoms, exacerbation of asthma, potential for abuse and addiction.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, benzodiazepines, other opioids, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially severe and unpredictable potentiation of CNS depressant effects or other effects.
* **Anticholinergics:** Increased risk of urinary retention and severe constipation, which may lead to paralytic ileus.
* **CYP3A4 Inhibitors/Inducers:** May alter dihydrocodeinone plasma concentrations, increasing toxicity or reducing efficacy.
## Monitoring
* Respiratory rate, depth, and pattern.
* Level of consciousness and sedation.
* Bowel function for signs of constipation.
* Pain relief and effectiveness.
* Signs of opioid dependence or withdrawal if used chronically.
## Clinical Pearls
* Dihydrocodeinone is a potent opioid; adherence to recommended doses is crucial.
* Concomitant use with other CNS depressants significantly increases the risk of respiratory depression.
* Constipation is a common and expected side effect; prophylactic bowel regimens should be considered for patients on chronic therapy.
* Patients should be advised against driving or operating heavy machinery due to potential sedation.
* Consider the potential for abuse, addiction, and diversion.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before initiating or modifying therapy.*
